Moving Mountains with Molecules in Tardive Dyskinesia: Optimizing Strategies for Challenging Cases

Tardive dyskinesia (TD) remains a significant challenge in psychiatric practice, requiring early recognition and a tailored treatment approach. This session will equip clinicians with practical strategies to enhance TD screening, assessment, and monitoring, including the use of validated rating scales and telemedicine tools. Attendees will refine their ability to differentiate TD from other movement disorders using key diagnostic criteria and clinical features. Additionally, the session will provide a deep dive into the latest clinical data on VMAT-2 inhibitors, highlighting pharmacologic distinctions that can guide personalized treatment selection and dose adjustments. Join us for an insightful discussion on optimizing TD management in complex cases.

Supported by independent educational grants from Neurocrine Biosciences, Inc. and Teva Pharmaceuticals, U.S.A, Inc.